Recognition and attitudes of Korean physicians toward fecal microbiota transplantation: a survey study
2
조회
0
다운로드
5
인용
0
참고문헌
키워드
초록
Background/Aims: Fecal microbiota transplantation (FMT) represents a treatment option for recurrent Clostridioides difficile infection (CDI). Recently, FMT has been investigated in various clinical settings other than CDI. This study examined Korean physicians’ recognition of FMT and their attitudes toward this procedure. Methods: An online questionnaire included questions on indications for FMT, the FMT process, physicians’ attitudes toward FMT for the treatment of CDI and non-CDI diseases, and possible concerns. Results: Finally, 107 physicians responded to this survey: 66 (61.7%) had experience of performing FMT, and 86 (80.4%) replied that they were willing to perform FMT for CDI. Two-thirds of physicians (63.6%, n = 68) would perform FMT for recurrent CDI on patients who had at least three recurrences. The most common obstacle to performing FMT for the treatment of CDI was the lack of regulations or guidelines (55.1%, n = 59). Seventy-seven (72.0%) physicians would consider FMT for non- CDI diseases when conventional treatment had failed. The most common obstacle for FMT for the treatment of non-CDI diseases was low treatment efficacy (57.0%, n = 61). Conclusions: Two-thirds of Korean physicians had experience of performing FMT, and many performed FMT for recurrent CDI. The results of this study will prove useful to researchers and practitioners in FMT in Korea.
Abstract
Background/Aims: Fecal microbiota transplantation (FMT) represents a treatment option for recurrent Clostridioides difficile infection (CDI). Recently, FMT has been investigated in various clinical settings other than CDI. This study examined Korean physicians’ recognition of FMT and their attitudes toward this procedure. Methods: An online questionnaire included questions on indications for FMT, the FMT process, physicians’ attitudes toward FMT for the treatment of CDI and non-CDI diseases, and possible concerns. Results: Finally, 107 physicians responded to this survey: 66 (61.7%) had experience of performing FMT, and 86 (80.4%) replied that they were willing to perform FMT for CDI. Two-thirds of physicians (63.6%, n = 68) would perform FMT for recurrent CDI on patients who had at least three recurrences. The most common obstacle to performing FMT for the treatment of CDI was the lack of regulations or guidelines (55.1%, n = 59). Seventy-seven (72.0%) physicians would consider FMT for non- CDI diseases when conventional treatment had failed. The most common obstacle for FMT for the treatment of non-CDI diseases was low treatment efficacy (57.0%, n = 61). Conclusions: Two-thirds of Korean physicians had experience of performing FMT, and many performed FMT for recurrent CDI. The results of this study will prove useful to researchers and practitioners in FMT in Korea.
참고문헌 (30)
- Quraishi MN, "Systematic review with meta-analysis : the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection", Aliment Pharmacol Ther, 46, pp.479~493 (2017)
- Gweon TG, "Hematologic diseases : high risk of Clostridium difficile associated diarrhea", World J Gastroenterol, 20, pp.6602~6607 (2014)
- Loo VG, "Host and pathogen factors for Clostridium difficile infection and colonization", N Engl J Med, 365, pp.1693~1703 (2011)
- Ofori E, "Community-acquired Clostridium difficile : epidemiology, ribotype, risk factors, hospital and intensive care unit outcomes, and current and emerging therapies", J Hosp Infect, 99, pp.436~442 (2018)
- Kim B, "Ribotype variability of Clostridioides difficile strains in patients with hospital-acquired C. difficile infections, community-acquired C. difficile infections, and colonization with toxigenic and non-toxigenic strains of C. difficile", Anaerobe, 60, pp.102086~ (2019)
- van Nood E, "Duodenal infusion of donor feces for recurrent Clostridium difficile", N Engl J Med, 368, pp.407~415 (2013)
- Mullish BH, "The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications : joint British Society of Gastroenterology(BSG)and Healthcare Infection Society(HIS)guidelines", Gut, 67, pp.1920~1941 (2018)
- Tae-Geun Gweon, "Clinical Practice Guidelines for Fecal Microbiota Transplantation in Korea", Journal of Neurogastroenterology and Motility (JNM), 28(1), pp.28~42 (2022), 대한소화기 기능성질환∙운동학회[DOI]
- Zipursky JS, "Physician attitudes toward the use of fecal microbiota transplantation for the treatment of recurrent Clostridium difficile infection", Can J Gastroenterol Hepatol, 28, pp.319~324 (2014)
- Zipursky JS, "Patient attitudes toward the use of fecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection", Clin Infect Dis, 55, pp.1652~1658 (2012)
- El-Salhy M, "Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study", Gut, 69, pp.859~867 (2020)
- Costello SP, "Effect of fecal microbiota transplantation on 8-week remission in patients with ulcerative colitis : a randomized clinical trial", JAMA, 321, pp.156~164 (2019)
- Kyeong Ok Kim, "Fecal Microbiota Transplantation: An Update on Clinical Practice", Clinical Endoscopy, 52(2), pp.137~143 (2019), 대한소화기내시경학회[DOI]
- Tae-Geun Gweon, "Next Generation Fecal Microbiota Transplantation", Clinical Endoscopy, 54(2), pp.152~156 (2021), 대한소화기내시경학회[DOI]
- 권태근, "대변 세균총 이식으로 치료된 난치성 위막성 대장염 2예", 대한내과학회지, 84(3), pp.395~399 (2013), 대한내과학회[DOI]
- 방병욱, "Fecal Microbiota Transplantation for Refractory and Recurrent Clostridium difficile Infection: A Case Series of Nine Patients", 대한소화기학회지, 69(4), pp.226~231 (2017), 대한소화기학회
- Yoon Hyuk, "Factors Related to Outcomes of Fecal Microbiota Transplantation in Patients with Clostridioides difficile Infection", Gut and Liver, 15(1), pp.61~69 (2021), 거트앤리버 소화기연관학회협의회[DOI]
- Gweon TG, "Fecal microbiota transplantation using upper gastrointestinal tract for the treatment of refractory or severe complicated Clostridium difficile infection in elderly patients in poor medical condition : the first study in an Asian country", Gastroenterol Res Pract, 2016, pp.2687605~ (2016)
- Moayyedi P, "Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial", Gastroenterology, 149, pp.102~109 (2015)
- Paramsothy S, "Multidonor intensive faecal microbiota transplantation for active ulcerative colitis : a randomised placebo-controlled trial", Lancet, 389, pp.1218~1228 (2017)
- Halkjær SI, "Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome : results from a randomised, double-blind placebo-controlled study", Gut, 67, pp.2107~2115 (2018)
- "Guidance for industry: enforcement policy regarding investigational new drug requirements for use of fecal microbiota for transplantation to treat clostridium difficile infection not responsive to standard therapies;availability" (2013)[URL]
- Smith MB, "Policy : how to regulate faecal transplants", Nature, 506, pp.290~291 (2014)
- Terveer EM, "How to : establish and run a stool bank", Clin Microbiol Infect, 23, pp.924~930 (2017)
- Hamilton MJ, "Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection", Am J Gastroenterol, 107, pp.761~767 (2012)
- Seo Hyun Soo, "Laboratory Aspects of Donor Screening for Fecal Microbiota Transplantation at a Korean Fecal Microbiota Bank", Annals of Laboratory Medicine, 41(4), pp.424~428 (2021), 대한진단검사의학회[DOI]
- DeFilipp Z, "Drug-resistant E. coli bacteremia transmitted by fecal microbiota transplant", N Engl J Med, 381, pp.2043~2050 (2019)
- Jiang ZD, "Physician attitudes toward the use of fecal transplantation for recurrent Clostridium difficile infection in a metropolitan area", Clin Infect Dis, 56, pp.1059~1060 (2013)
- Paramsothy S, "Gastroenterologist perceptions of faecal microbiota transplantation", World J Gastroenterol, 21, pp.10907~10914 (2015)
- Ianiro G, "Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic", Gut, 69, pp.1555~1563 (2020)